Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 9/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL644571 | 0.92 | HSP90AA1 (0.42) | HSP90AA1POLBALDH1A1 | |
| SCHEMBL646290 | 0.90 | HSP90AA1 (0.48) | HSP90AA1POLBALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL645947 | 0.89 | HSP90AA1 (0.55) | HSP90AA1POLBALDH1A1LMNA | |
| SCHEMBL645737 | 0.87 | HSP90AA1 (0.54) | HSP90AA1POLB | |
| SCHEMBL645560 | 0.87 | HSP90AA1 (0.54) | HSP90AA1POLB | |
| SCHEMBL647638 | 0.86 | HSP90AA1 (0.53) | HSP90AA1POLBALDH1A1HSD17B10 | |
| SCHEMBL647188 | 0.86 | HSP90AA1 (0.52) | HSP90AA1POLBALDH1A1 | |
| SCHEMBL646621 | 0.86 | HSP90AA1 (0.52) | HSP90AA1POLBALDH1A1 | |
| SCHEMBL646679 | 0.85 | HSP90AA1 (0.55) | HSP90AA1 | |
| SCHEMBL644915 | 0.85 | HSP90AA1 (0.51) | HSP90AA1POLBALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2023922-B1 | TRIAZOLE DERIVATIVES II | MERCK PATENT GMBH (DE) | 2012-07-11 | — | — | EP | claimed |
| US-8119795-B2 | Triazole derivatives II | MERCK PATENT GMBH (DE) | 2012-02-21 | — | — | US | claimed |
| US-20100022540-A1 | TRIAZOLE DERIVATIVES II | MERCK PATENT GESELLSCHAFT (DE) | 2010-01-28 | — | — | US | claimed |
| EP-2023922-B1 | TRIAZOLE DERIVATIVES II | MERCK PATENT GMBH (DE) | 2012-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022540-A1 | TRIAZOLE DERIVATIVES II | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885POLB 3458/4885ALDH1A1 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.